Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Signifor

This page shows the latest Signifor news and features for those working in and with pharma, biotech and healthcare.

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

New data for Recordati’s Isturisa reinforces benefit in Cushing’s disease

Isturisa was originally developed by Novartis, although Recordati licensed global rights from the company in July 2019 for $390m upfront in a deal that also included rights to Signifor and Signifor

Latest news

  • FDA approves Recordati’s Cushing disease drug Isturisa FDA approves Recordati’s Cushing disease drug Isturisa

    Signifor and its longer-acting follow-up Signifor LAR – both based on the somatostatin analogue pasireotide. ... That would add to pro forma sales of around $75m last year for the Signifor franchise, with potential to raise that to $100m, he said.

  • Novartis' acromegaly therapy cleared by FDA Novartis' acromegaly therapy cleared by FDA

    In trials, Signifor LAR showed superior efficacy to older somatostatin analogues, as measured by higher rates of biochemical control of GH and IGF-1 levels. ... Signifor LAR needs to be given just once a month, allowing it to compete head-to-head with

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    This first approval of Signifor in acromegaly marks a much needed advance in the treatment of this rare disease.". ... Signifor LAR has been submitted worldwide for the treatment of acromegaly, with an application filed in the US earlier this year, said

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    Could add to Signifor’s indications. A phase III trial of Novartis' somatostatin analogue Signifor has suggested it could be effective for the growth hormone disorder acromegaly. ... The shorter-acting, subcutaneous form of Signifor was approved in 2012

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links